Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer

I. Vergote, N. Finkler, J. del Campo, A. Lohr, J. Hunter, D. Matei, J. Kavanagh, J. B. Vermorken, L. Meng, M. Jones, G. Brown, S. Kaye

Research output: Contribution to journalArticle

88 Scopus citations

Fingerprint Dive into the research topics of 'Phase 3 randomised study of canfosfamide (Telcyta<sup>®</sup>, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences